SI0970955T1 - Paroxetine methanesulfonate - Google Patents

Paroxetine methanesulfonate

Info

Publication number
SI0970955T1
SI0970955T1 SI9930002T SI9930002T SI0970955T1 SI 0970955 T1 SI0970955 T1 SI 0970955T1 SI 9930002 T SI9930002 T SI 9930002T SI 9930002 T SI9930002 T SI 9930002T SI 0970955 T1 SI0970955 T1 SI 0970955T1
Authority
SI
Slovenia
Prior art keywords
paroxetine methanesulfonate
paroxetine
methanesulfonate
Prior art date
Application number
SI9930002T
Other languages
English (en)
Inventor
Andrew Simon Craig
David Alan Jones
Deirdre O'keeffe
Neal Ward
Victor W Jacewicz
Michael Urquhart
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0970955(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814316.7A external-priority patent/GB9814316D0/en
Priority claimed from GBGB9821732.6A external-priority patent/GB9821732D0/en
Priority claimed from GBGB9902935.7A external-priority patent/GB9902935D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of SI0970955T1 publication Critical patent/SI0970955T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI9930002T 1998-07-02 1999-04-23 Paroxetine methanesulfonate SI0970955T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds
GBGB9821732.6A GB9821732D0 (en) 1998-10-06 1998-10-06 Novel compound
GBGB9902935.7A GB9902935D0 (en) 1999-02-10 1999-02-10 Novel compound
EP99303151A EP0970955B1 (en) 1998-07-02 1999-04-23 Paroxetine methanesulfonate

Publications (1)

Publication Number Publication Date
SI0970955T1 true SI0970955T1 (en) 2001-02-28

Family

ID=27269380

Family Applications (3)

Application Number Title Priority Date Filing Date
SI9930002T SI0970955T1 (en) 1998-07-02 1999-04-23 Paroxetine methanesulfonate
SI9930009T SI1020464T1 (en) 1998-07-02 1999-04-23 Paroxetine methansulfonate
SI9930482T SI1089996T1 (en) 1998-07-02 1999-04-23 Paroxetine methanesulfonate acetonitrile solvate 1:1

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI9930009T SI1020464T1 (en) 1998-07-02 1999-04-23 Paroxetine methansulfonate
SI9930482T SI1089996T1 (en) 1998-07-02 1999-04-23 Paroxetine methanesulfonate acetonitrile solvate 1:1

Country Status (34)

Country Link
US (4) US6063927A (enExample)
EP (5) EP1089996B1 (enExample)
JP (1) JP2002519422A (enExample)
KR (1) KR20010053336A (enExample)
CN (1) CN1127502C (enExample)
AR (2) AR011759A1 (enExample)
AT (4) ATE251155T1 (enExample)
AU (4) AU3619199A (enExample)
BE (3) BE1012403A5 (enExample)
BR (1) BR9911682A (enExample)
CA (1) CA2269999A1 (enExample)
CH (1) CH689805A8 (enExample)
DE (5) DE29907248U1 (enExample)
DK (7) DK0970955T3 (enExample)
ES (4) ES2209428T3 (enExample)
FI (2) FI112077B (enExample)
FR (2) FR2780728B1 (enExample)
GB (5) GB2367003A (enExample)
GR (3) GR990100140A (enExample)
HU (1) HUP0102334A3 (enExample)
IE (5) IES81166B2 (enExample)
IL (1) IL140628A (enExample)
IT (1) IT1312540B1 (enExample)
LU (1) LU90388B1 (enExample)
NL (4) NL1011875C2 (enExample)
NO (1) NO319030B1 (enExample)
NZ (1) NZ509180A (enExample)
PL (1) PL345214A1 (enExample)
PT (4) PT1089996E (enExample)
SE (1) SE9901462A0 (enExample)
SI (3) SI0970955T1 (enExample)
SK (1) SK20262000A3 (enExample)
TR (1) TR200100054T2 (enExample)
WO (1) WO2000001694A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
JP4081820B2 (ja) * 1997-02-27 2008-04-30 味の素株式会社 晶析装置及び晶析方法
EP1078925A1 (en) * 1997-06-10 2001-02-28 Synthon B.V. 4-Phenylpiperidine compounds
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20040028582A1 (en) * 1999-03-10 2004-02-12 Smithkline Beecham Corporation Crystallization process for producing fine crystal products
USPP12225P2 (en) 1999-06-01 2001-11-27 Florfis Ag Geranium plant named ‘Fislamda’
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
NZ523902A (en) * 2000-08-28 2004-05-28 Synthon Bv Paroxetine compositions and processes for making the same
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
EP1412350A1 (en) * 2001-08-02 2004-04-28 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
AU2006235230B8 (en) * 2005-04-07 2010-08-26 Chata Biosystems, Inc. Flow path conditioner system
AU2006315684A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
EP1966192B1 (en) * 2005-12-01 2012-10-17 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US20100093749A1 (en) * 2007-03-09 2010-04-15 Novartis Ag Compounds
US8119688B2 (en) * 2007-09-19 2012-02-21 Xy, Llc Differential evaporation potentiated disinfectant system
US20100249166A1 (en) * 2007-09-19 2010-09-30 Xy, Inc. Differential evaporation potentiated disinfectant system
FR2926552B1 (fr) * 2008-01-23 2010-03-26 Biocodex Procede de preparation de particules de stiripentol ayant une granulometrie definie
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法
CN104523645A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 甲磺酸帕罗西汀片芯及其包衣片的制备方法
US11111373B2 (en) 2018-12-05 2021-09-07 Chi Mei Corporation Polymethacrylate composition and optical device made therefrom, and display apparatus

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE99678C (enExample) *
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
GB8431478D0 (en) * 1984-12-13 1985-01-23 Beecham Group Plc Compounds
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
EP0223334B1 (en) * 1985-08-10 1991-07-10 Beecham Group Plc Process for the preparation of aryl-piperidine carbinols
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
DE3677712D1 (de) * 1985-10-21 1991-04-04 Honda Motor Co Ltd Methode zur steuerung des spulenstroms eines magnetventils, das die saufluftmenge eines innenverbrennungsmotors steuert.
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
KR930702000A (ko) * 1990-11-24 1993-09-08 데이빗 로버츠 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
CA2216934A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
AU721257B2 (en) * 1995-05-17 2000-06-29 Novo Nordisk A/S Process for preparing 4-aryl-piperidine derivatives
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
CA2234640A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
DE69739561D1 (de) * 1996-06-13 2009-10-15 Sumitomo Chemical Co Piperidin Derivative als Zwischenprodukte zur Herstellung von Paroxetine und Verfahren zu ihrer Herstellung
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
EP1078925A1 (en) * 1997-06-10 2001-02-28 Synthon B.V. 4-Phenylpiperidine compounds
JP2002505254A (ja) * 1998-02-06 2002-02-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー パロキセチン塩
SK13622000A3 (sk) * 1998-03-16 2001-03-12 Smithkline Beecham Plc Kryštalická forma paroxetínu, farmaceutický prostriedok a použitie
TR200002939T2 (tr) * 1998-04-09 2001-02-21 Smithkline Beecham Plc Paroksetin maleat
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat

Also Published As

Publication number Publication date
ATE195121T1 (de) 2000-08-15
PT102291B (pt) 2002-07-31
IT1312540B1 (it) 2002-04-22
DK1020464T3 (da) 2001-09-24
PT1020464E (pt) 2001-10-30
EP0970955B1 (en) 2000-08-02
NL1012272C1 (nl) 1999-07-12
SI1020464T1 (en) 2001-12-31
GB2367003A (en) 2002-03-27
GB0119695D0 (en) 2001-10-03
GB0216752D0 (en) 2002-08-28
WO2000001694A1 (en) 2000-01-13
FI112077B (fi) 2003-10-31
AU3619199A (en) 2000-01-24
NO991944D0 (no) 1999-04-23
NZ509180A (en) 2001-06-29
GB2352395B (en) 2004-02-11
DK199900176U3 (da) 1999-08-13
IE990344A1 (en) 2000-05-03
DE69900007D1 (de) 2000-09-07
DE69911774T2 (de) 2004-08-05
DE69900007T2 (de) 2001-06-07
DK200000390U1 (da) 2000-12-27
US6063927A (en) 2000-05-16
NL1011875A1 (nl) 2000-01-07
SE9901462L (enExample)
HUP0102334A3 (en) 2003-12-29
FI990922L (fi) 2000-01-03
HK1037877A1 (en) 2002-02-22
PT102291A (pt) 2000-05-31
GR990100140A (el) 2000-03-31
NO991944L (no) 2000-01-03
AU2392899A (en) 2000-01-20
FR2780728B1 (fr) 2001-02-16
NL1011875C2 (nl) 2000-03-24
PT970955E (pt) 2000-11-30
CH689805A5 (fr) 1999-11-30
AT3185U2 (de) 1999-11-25
DE19918588A1 (de) 2000-01-27
DE69911774D1 (de) 2003-11-06
BR9911682A (pt) 2001-12-26
US20020193406A1 (en) 2002-12-19
SE9901462D0 (sv) 1999-04-23
AU732211C (en) 2004-05-06
NO319030B1 (no) 2005-06-06
AR018197A1 (es) 2001-10-31
SK20262000A3 (sk) 2001-07-10
IES81166B2 (en) 2000-05-31
JP2002519422A (ja) 2002-07-02
GB9909505D0 (en) 1999-06-23
DE60000003D1 (de) 2001-08-09
LU90388B1 (fr) 2001-01-29
ITMI990866A1 (it) 2000-10-23
CN1127502C (zh) 2003-11-12
IES990343A2 (en) 2000-01-02
EP1020463A1 (en) 2000-07-19
NL1011874C1 (nl) 1999-07-12
GR3034328T3 (en) 2000-12-29
FI990922A0 (fi) 1999-04-23
CH689805A8 (fr) 2000-02-29
GB0026487D0 (en) 2000-12-13
AR011759A1 (es) 2000-09-13
GB9920332D0 (en) 1999-11-03
HUP0102334A2 (hu) 2002-05-29
ES2149044T3 (es) 2000-10-16
US20020035130A1 (en) 2002-03-21
CN1315949A (zh) 2001-10-03
DK199900554A (da) 2000-01-03
BE1012403A5 (fr) 2000-10-03
TR200100054T2 (tr) 2001-06-21
EP1020464B1 (en) 2001-07-04
GB2339428A (en) 2000-01-26
ES2157881T3 (es) 2001-09-01
PL345214A1 (en) 2001-12-03
ATE251155T1 (de) 2003-10-15
GB2377637A (en) 2003-01-22
IES20000893A2 (en) 2001-05-30
GB2336364B (en) 2000-05-10
EP1288214A1 (en) 2003-03-05
FR2780728A1 (fr) 2000-01-07
EP1089996A1 (en) 2001-04-11
EP1089996B1 (en) 2003-10-01
IL140628A0 (en) 2002-02-10
AU713877B3 (en) 1999-12-09
GR3036208T3 (en) 2001-10-31
FI4209U1 (fi) 1999-11-10
GR1003350B (el) 2000-03-29
KR20010053336A (ko) 2001-06-25
ATE202777T1 (de) 2001-07-15
DK0970955T3 (da) 2000-10-09
DE29907248U1 (de) 1999-09-09
AU713131B3 (en) 1999-11-25
ES2158778B1 (es) 2002-03-16
SE9901462A0 (sv) 2000-01-03
NL1012271C2 (nl) 1999-09-23
GB2352395A (en) 2001-01-31
DK199900234U1 (da) 2000-12-22
DE60000003T2 (de) 2002-03-21
FIU990190U0 (fi) 1999-04-23
BE1011664A6 (fr) 1999-11-09
EP0970955A1 (en) 2000-01-12
BE1012420A6 (fr) 2000-10-03
GB2336364A (en) 1999-10-20
AT3185U3 (de) 2000-01-25
IES20000894A2 (en) 2001-05-30
NL1012271A1 (nl) 1999-07-12
PT1089996E (pt) 2004-02-27
ES2158778A1 (es) 2001-09-01
IE20000633A1 (en) 2001-10-17
DK1089996T3 (da) 2004-02-09
CA2269999A1 (en) 2000-01-02
EP1020464A1 (en) 2000-07-19
ES2209428T3 (es) 2004-06-16
DK199900234U4 (da) 2000-12-22
US20010023253A1 (en) 2001-09-20
IL140628A (en) 2004-06-20
FR2802098A1 (fr) 2001-06-15
SI1089996T1 (en) 2004-04-30
AU732211B2 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
GB2352395B (en) Paroxetine methanesulfonate
GB2331534B (en) Centralizer
IL137329A0 (en) Vla-4 antagonists
EP1084142A4 (en) GPR35A RECEIVER
PL347397A1 (en) Substituted 3-aryl-pyrazoles
GB9816729D0 (en) Substituted cyclohexylaminopyrimidines
PL343378A1 (en) Paroxetine maleate
IL138478A0 (en) Paroxetine compositions
HUP9902131A3 (en) Pusher construction
PL345866A1 (en) Substituted cyclooctadepsipeptides
EP1083909A4 (en) hCEPR RECEPTOR
TW407677U (en) Form
EP1109565A4 (en) GABAB1AA RECEPTOR
GB9825849D0 (en) Receptor
GB9806323D0 (en) Services-connections for trailer-vehicles
HU9800230V0 (en) Bandbaluster for boondary
PL327557A1 (en) Micro-agitator for emulssions
GB9813279D0 (en) Modified receptor
TW342607U (en) Improved structure for dripping-type filtering-trough
TW368021U (en) Improved structure for hinge
TW366045U (en) Improved structure for hinge
PL328752A1 (en) Microprobe
TW356183U (en) Improved structure for wind-shielding block
TW345033U (en) Improvement for filtering-core
TW345035U (en) Improvement for filtering-core